The document approved in relation to psychotropic substances, entitled
“On the Establishment of the 2026 Domestic Quota for Certain Substances Subject to Special Control That Are Not Subject to International Control, as well as for Certain Medicinal Products Equated to Pharmaceutical Products Subject to Special Control,”
was jointly signed on January 30, 2026, by the Minister of Health, Mikheil Sarjveladze, and the Minister of Internal Affairs, Gela Geladze.
What the document regulates
The document establishes Georgia’s domestic quotas for 2026 for substances that:
-
are not subject to international narcotic control,
-
require special state supervision within Georgia,
-
or are equated to pharmaceutical products subject to special control.
Accordingly, the state determines the amount (in grams/kilograms) of these substances that may be legally used within the country, including for importation, production, and medical use.
Quotas established for 2026 apply to the following substances:
-
Baclofen – 1,000 g
-
Gabapentin – 80,000 g
-
Zopiclone – 800 g
-
Pregabalin – 120,000 g
-
Trihexyphenidyl hydrochloride – 8,000 g
From a healthcare perspective, these substances are widely used in neurology, psychiatry, and pain management. However, due to their high potential for addiction and non-medical use, strict state control is deemed necessary.
What has changed?
The previous year’s regulation set the following quotas:
-
Zopiclone – 400 g
-
Pregabalin – 50,000 g
-
Trihexyphenidyl hydrochloride – 10,000 g
Under that regulation, gabapentin and baclofen were not subject to quota restrictions in 2025, whereas they were added in 2026.
It is noteworthy that neither the previous year’s list nor the current one includes zaleplon, dextromethorphan, or tropicamide, which were present in the lists through 2023. This may be interpreted as an indication of a shift in state policy regarding substances subject to special control.
